Drug formulation and dosing
The formulation of liothyronine sodium sustained-release tablets was developed by Noor Research & Educational Institute (TAVAN). Using Avicel PH-102 and HPMC in formulation of tablets sustained the drug release of T3 for over 10 h. The in vitro dissolution study was carried out in 500 ml, pH 6.8 phosphate buffer using United States Pharmacopeia Apparatus I, basket method, at a speed of 100 rpm and temperature of 37 C. Levothyroxine sodium (LT4) plus SR-T3 was administered based on the previous levothyroxine dosage which was at a weight-based dose of ~ 1.6 mcg/kg. Each combination was equal to 100 µg Levothyroxine.The 2012 ETA, suggested L-T4 + L-T3 combination treatment with a dose ratio between 13:1 and 20:1 by weight [